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Editorial on the Research Topic
Transplantation of Marginal Organs—Immunological Aspects and Therapeutic Perspectives
In organ transplantation, shortage of available grafts has resulted in a continuously growing use of
kidneys, livers, lungs, and hearts from elderly donors, often with comorbidities. The percentage of
≥60-year-old deceased kidney donors reported to the Collaborative Transplant Study (CTS) from
Europe was 21% during 2000 to 2001 and increased to as high as 42% during 2016 to 2017 (1). Due
to a decreased number of functional tissue and inflammation-mediated alloantigen expression, these
marginal organs from expanded criteria donors (ECD) are considered to be more vulnerable to
immune attack and show impaired survival rates. Different criteria are used in different organ types
to define ECDs. In kidney transplantation, besides a donor age above 59, a history of hypertension,
increased creatinine and cerebrovascular cause of death are key factors impacting the quality of the
deceased donor organ. Articles in this Research Topic highlight the problems that are encountered
in transplantation of marginal organs and propose novel diagnostic and methodological
approaches, including improvement of organ allocation strategies, use of alternative therapeutic
regimens and utilization of modern machine perfusion (MP) techniques that enable estimation of
organ quality, preconditioning of donors, depletion of immune cells and genetic silencing
of alloantigens.
Gerbase-DeLima et al. underline with their large single-center analysis of more than 5,000 kidney
transplantations the importance of the awareness of risk that is associated with different
combinations of donor and recipient age. They report lower death censored graft and patient
survival in recipients of kidneys from elderly donors and higher graft but lower patient survival in
elderly recipients. Also factors, such as time on dialysis and HLA match, influenced outcome
differentially in different recipient and donor age combinations. Noble et al. describe in their
comprehensive review immunological aspects of kidney transplantation in elderly recipients with
organs from marginal donors and highlight therapeutic options that could help to prevent side
effects, such as toxicity and development of cancer. Echterdiek et al. report, despite a negative trend
in demographic parameters, an improving outcome of kidneys from ≥70-year-old donors in Europe
over the years, most probably due to an improving physiology of elderly donors. This finding could
encourage to increase the donor pool also in other parts of the world, such as the United States,
where organs from elderly donors are currently discarded at a high rate.
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Eurotransplant (ET) Senior Program (ESP) is an “old-for-
old” allocation scheme in which kidneys from ≥65-year-old
deceased donors are allocated independent of HLA matching
to ≥65-year-old recipients locally in order to prevent further
ischemic injury in an already vulnerable organ during the
transport to a better matched recipient. Increasingly more
kidney transplantations are currently performed via ESP and
their percentage among all performed deceased donor kidney
transplantations rose in ET countries from 9% in 2000 to 18% in
2019 (2). Dreyer and de Fijter advocate in their review the
introduction of a restricted form of matching in ESP for only
the HLA-DR locus instead of the three HLA loci that are
considered in regular kidney allocation. They claim that this
procedure can be performed locally without prolonging the cold
ischemia time (CIT) and is expected to result in less rejections
and mortality. Prolonged CIT is also in liver transplantation a
critical factor that affects graft and patient survival. Lozanovski
et al. found in their CTS analysis of more than 40,000 liver
transplant recipients that the negative influence of CIT on
outcome is much stronger in patients with hepatitis C-related
cirrhosis than for example in patients with alcoholic cirrhosis or
in patients with hepatocellular carcinoma and low “model of
end-stage liver disease” scores. They, therefore, suggest that
original disease should also be implemented as a criterion in
allocation of livers.
Due to the general trend of increasing donor age, delayed
graft function (DGF) is observed in a growing proportion of
recipients of deceased donor kidney transplants. Morath et al.
analyzed the influence of DGF in association with pre-
sensitization in kidney transplantations performed between
2008 and 2017. Besides the known non-immunological factors,
such as high donor age and prolonged ischemia time, the pre-
transplant presence of broad alloantibody reactivity was found to
be a significant predictor of DGF, also in this more recent era of
transplantation during which sensitive antibody testing was
practiced. Development of DGF itself doubled the risk of graft
loss which, however, increased further if the patient had HLA or
donor-specific HLA antibodies before transplantation. These
findings indicate that special measures are necessary during
allocation of organs from elderly donors, especially to pre-
sensitized patients.
Robust measures of organ quality are required for reliable
prediction of successful outcomes in the use of marginal organs.
However, organ quality is difficult to assess, in particular, within
the narrow window of time to transplantation. In this setting
molecular diagnostics could complement the clinical and
histopathological evaluation of tissue quality by capturing
additional information on immune- and non–immune-
mediated injury as well as repair mechanisms. Von Moos et al.
reviewed the current state of quality assessment in donor kidneys
using clinical scores, histopathology and perfusion
characteristics with an emphasis on molecular analyses. They
describe shortcomings of available methods and studies. The
review highlights advances made in the integration of molecular
analyses with clinical data and future studies necessary to
perform. Along the same line, Hruba et al. investigated in
different donor categories transcriptome profiles of allograft
biopsies with borderline changes. When compared with
standard criteria or living donor kidneys, ECD kidneys showed
higher expression of transcripts related to inflammation and
extracellular matrix remodeling. These changes are expected to
aggravate alloimmune responses and influence outcomes.
Boissier et al. compared the cellular components and the
transcriptomic and vasculogenic profiles in the peri-renal
adipose tissue of kidneys from ECDs and optimal donors. Peri-
renal adipose tissue of ECDs was found to display an age-
dependent inflammatory signature that was associated with
early graft dysfunction. NK-cell subsets were recruited
differentially in the peri-organ environment of kidney grafts
from elderly donors. This novel evidence indicate that peri-
renal adipose tissue, which can be gained non-invasively and
timely, represents a valuable source of donor material to assess
inflammatory changes that affect organ quality and function.
Corradetti et al. highlight in their case report cholesterol
embolism as a rare but severe adverse event that can occur in
transplantation of marginal donor kidneys and report its
successful treatment with the prostaglandin I2 analog iloprost.
Causality still has to be shown here and controlled studies are
necessary to assess the true value of the iloprost therapy.
MP is on the way of becoming a core technology in the use of
ECD organs that allows not only the estimation of organ quality
prior to transplantation but also enables intervention for
improved preservation, (re)conditioning and regeneration of
organs. Furthermore, it has the potential for a medical
revolution toward organ engineering. Resch et al. review in
detail the beneficial use of oxygenated hypothermic and
normothermic MP and describe findings which indicate that
MP prolongs the graft preservation time significantly and allows,
during the perfusion procedure, treatments generating chimeric
organs and enabling immunological changes, defatting,
reduction of inflammation and elimination of hepatitis C. They
state that improved graft function after MP can most likely be
explained by amelioration of ischemia/reperfusion injury (IRI)
and assessment of the graft’s viability and function prior to
transplantation. Kvietkauskas et al. summarize in their review
experimental studies and clinical trials on MP-associated
treatment strategies and focus hereby on inhibition of
allorecognition pathways. Specifically, they show evidence that
MP protects the organ from inadequate activation of innate
immunity by decreasing IRI. Unfortunately, established clinical
standards in MP-protocols are still missing.
In several experimental models, MHC-silenced cells were
shown to be protected against allogeneic immune responses (3,
4). Yuzefovych et al. demonstrate a sub-normothermic ex vivo
perfusion system in rats which enables the delivery of lentiviral
vectors that encode small hairpin RNAs to permanently silence
MHC antigens. If feasible and safe in humans, generation of
immunologically silenced organs raise great expectations to solve
the major problems of organ transplantation, such as rejection
and side effects of immunosuppressive regimens. Donor hearts
have significant leukocyte reservoirs which can activate recipient
leukocytes and initiate acute rejection upon transplantation.
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Critchley et al. demonstrate in an experimental porcine heart
transplantation model that, as compared to static cold storage,
hypothermic MP with cardioplegic solution reduces
immunogenicity of the organ significantly via elimination of
resident leukocytes. Besides a pro-inflammatory cytokine
pattern, a pro-survival- and reduced ischemia-related profile
was observed after hypothermic MP that could explain the
improvement in graft viability.
In addition toMP-technology, the clinical expertise of transplant
surgeons is of great importance to both accept and allocate organs
from ECDs to suitable recipients. Kahn et al. compared the outcome
of liver transplants from ECDs versus non-ECDs and show
evidence that, if a well-standardized allocation strategy based on
clinical facts is used, the outcome of ECD livers is not compromised
with a 90-day mortality of only 3.6%.
Dezfouli et al. compared, in a large animal model, anti-
inflammatory effects of preconditioning of kidney donors after
brain death with different therapeutic regimens. Interestingly,
oral administration of calcineurin inhibitors as well as inhibitors
of mammalian target for rapamycin decreased TNF-alpha
expression more effectively than the routinely administered
intravenous steroids, indicating that it would be worth to
investigate in additional studies the protective effect of oral
donor preconditioning on IRI.
The present Research Topic proves that transplantation of
ECD organs has become a major issue in organ transplantation
and describes solutions to the problem.
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